<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000269430">
  <TermName>valacyclovir</TermName>
  <TermPronunciation>(VAL-uh-SY-kloh-veer)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A substance that is being studied in the prevention of fungal, bacterial, and viral infections in patients undergoing donor stem cell transplantation with cells that are infected with cytomegalovirus. It belongs to the family of drugs called antivirals.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000710261" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;valacyclovir&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000710262" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;valaciclovir&quot;" language="es" id="_4"/>
  <SpanishTermName>valaciclovir</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Sustancia en estudio para la prevención de infecciones fúngicas, bacterianas y víricas en los pacientes que experimentan un trasplante de células madre de donantes con células infectadas por citomegalovirus. Es un tipo de antivírico.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2002-12-21</DateFirstPublished>
</GlossaryTerm>
